ANL compared with APGE: revenue, margins and what each company keeps, and the suppliers and customers both name

ANLAdlai Nortye Ltd.

Mkt capRevenueRevenue

APGEApogee Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ANLAdlai Nortye Ltd.

APGEApogee Therapeutics, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

ANL

No earnings history for ANL.

APGE

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±0.6%▼−0.14%×0.17

Q1 FY26±7.8%▲+1.89%×0.24

Q3 FY25±8.7%▲+3.77%×0.44

Aug 11 '25±7.7%▼−2.09%×0.27

= impliedANL realized, solidAPGE realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

ANLAdlai Nortye Ltd.

9.41· pre 9.41· delayed

Mkt cap$898.8M

APGEApogee Therapeutics, Inc.

135.07· pre 135.10· delayed

Pre-marketNov 2 '26delayed

Mkt cap$10.2B

Compare

Pre-marketNov 2 '26delayed

ANLAdlai Nortye Ltd.

APGEApogee Therapeutics, Inc.

9.41pre 9.41delayed

Price

135.07pre 135.10delayed

$898.8M

Mkt cap

$10.2B

ANL9.41vsAPGE135.07Pre-marketNov 2 '26delayed